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Abstract
Background: Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although
microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be
involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel
therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing
chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to
target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This
double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days
administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut
microbiota, and serum biomarkers of inflammation and oxidative stress.
Results: Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same
hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant
differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9;
placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after
treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in
the supplement group. When groups were compared, the supplement group showed significantly higher serum
cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group
showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant
differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota
evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group.
Conclusions: The combined administration of the supplement with hydrolyzed diet over 180 days was safe and
induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study
was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to
dietary treatment of this supplement on intestinal histology and CIBDAI.
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Background
Inflammatory bowel disease (IBD) in dogs is a chronic
gastrointestinal tract disorder of unknown cause [1, 2],
although the mucosal immune system, genetic suscepti-
bility, and the enteric microenvironment (nutrition and
microbiota) are considered to be important in its patho-
genesis [3–5]. Treatment protocols for IBD combine diet
modification, antibacterials and immunosuppressive
therapy [6], aiming at reducing intestinal inflammation
and restoring gut normobiosis. Dietary modification is
considered an adequate therapeutic starting point, since
most IBD dogs respond positively to dietary manage-
ment alone [7]. Dogs that do not respond or respond
partially, require further treatment with antibiotics and/
or immunosuppressive drugs like glucocorticoids, which
can be associated with severe side effects [4, 8–10].
Ideally, any long-term treatment protocol for IBD should
aim at maintaining patients in clinical remission for as
long as possible by adequately combining such thera-
peutic modalities while intending to minimize associated
side effects.
Chondroitin sulfate (CS), a natural glycosaminoglycan
present in the extracellular matrix, has been suggested
to reduce the incidence and severity of relapses in
human IBD [11]. CS inhibits nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) activity [11],
which is also a suggested component of the anti-
inflammatory activity of glucocorticoids and cyclospor-
ine A [12]. NF-κB is markedly increased in IBD [11, 13].
Oral CS might therefore reduce intestinal inflammation
and benefit dogs with IBD.
Oxidative stress is also believed to play a key role in
the pathogenesis of IBD [14]. Paraoxonase-1 (PON1), an
antioxidant enzyme used as a biomarker of oxidative
stress and inflammation in human IBD [15], could also
serve as a biomarker in dogs with IBD given the similar-
ities between human and canine IBD. In human IBD,
lower PON1 serum concentrations are associated with
increased inflammation and disease activity [16]. De-
creasing oxidative stress, shown as an increased PON1,
could therefore be an effective endpoint for IBD treat-
ment. Decreased serum TAC levels have been reported
in human patients with ulcerative colitis and Crohn’s
disease [17].
Lower bacterial diversity and altered microbial commu-
nities have been reported in canine IBD [2, 4, 5, 18, 19].
Orally administered prebiotics promote the growth of
beneficial gut microbiota [20–22]. Short chain fatty acids
(SCFA), especially butyrate, which is the preferential
source of energy for colonocytes, help maintaining the in-
testinal mucosal barrier [23, 24]. A reduction in SCFA
producing bacteria, especially Faecalibacterium spp. and
Fusobacteria, has been reported in dogs with IBD [5, 19].
Large-bowel fermentation of resistant starch increases
butyrate production [25]. Consequently, oral administra-
tion of resistant starch could benefit IBD patients by in-
creasing butyrate levels in their gut.
A dietary supplement containing CS and prebiotics
(resistant starch, β-glucans and mannanoligosaccharides
(MOS)) was developed to target intestinal inflammation,
oxidative stress and gut dysbiosis. Our research hypothesis
was that long-term administration of this supplement is
safe and helps to decrease intestinal inflammation and
oxidative stress and restore normobiosis. The purpose of
this study was therefore to evaluate the effects of this sup-
plement on clinical disease activity, intestinal histology,
gut microbiota, and selected serum biomarkers in dogs
with IBD over a time course of 180 days.
Methods
Dogs
This was a multicentric randomized double-blind placebo-
controlled study using client-owned dogs. All animal
owners gave written informed consent. The protocol was
reviewed and approved by the Animal Experimentation
Committee of the Complutense University of Madrid
(UCM). Both the owners and the investigators were
blinded to treatment assignment until the end of the study.
Inclusion criteria included dogs with a minimum age
of 1 year, persistent (>3 weeks in duration) gastrointes-
tinal signs, confirmation of IBD by histologic evaluation
of biopsy samples and a baseline score of at least 4 on
the canine IBD activity index (CIBDAI) [1]. A diagnostic
exclusion protocol was carried out in all patients in
order to rule out other possible causes of chronic diar-
rhea, including urinalysis, abdominal ultrasound, fecal
exam, CBC and serum biochemistry. Animals were ex-
cluded if they presented with significant extra-intestinal
disease, intestinal neoplasia, or severe hypoproteinemia
(serum albumin <1.8 g/dL), if they had not been ad-
equately dewormed within 60 days prior to trial entry,
and if they had received antibiotics, prebiotics or probio-
tics 7 days prior to inclusion, or glucocorticoids 14 days
prior to inclusion. Pregnant bitches were excluded.
Treatment was initiated 15 days after endoscopy. Dogs
with biopsy-confirmed IBD were then randomized in a
1:1 allocation ratio by means of a computer-generated
schedule into one of the 2 treatment groups: placebo
and supplement. All dogs were switched to a hydrolyzed
diet (Hypoallergenic, Royal Canin Ibérica SA, Madrid,
Spain) which was maintained during the course of the
study. Dogs in the placebo group (group A; n = 14) re-
ceived a placebo powder (containing only excipients and
flavorings) orally once daily, and dogs in the supplement1
group (group B; n = 13) received an oral daily dose per kg
of bodyweight of 215 mg α-glucan butyrogenic resistant
starch, 10 mg CS, and 26 mg β-glucans and MOS for
180 days. A rescue protocol was available in the case of
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clinical relapse; specifically, if the veterinarian responsible
for the case decided that a considerable worsening had
occurred since last visit, patients were administered a
combination of metronidazole (10 mg/kg, PO, BID) for
21 days, ranitidine (5 mg/kg, PO, SID) and metoclopra-
mide (0.5 mg/kg, PO, BID) for 60 days, and tapering doses
of oral prednisone (1 mg/kg BID for 10 days, followed by
0.5 mg/kg BID for 10 days, 0.5 mg/kg SID for 10 days, and
0.5 mg/kg EOD for 30 days) [26]. Relapsed cases that re-
ceived the rescue protocol were excluded from the final
data analysis.
Evaluations
CIBDAI scores and serum biomarkers were monitored
at the initial visit (15 days prior to treatment start) and
after 30, 60, 90, 120 and 180 days of treatment. Fasting
blood samples were collected to measure serum bio-
markers of inflammation (C-reactive protein (CRP)) and
oxidative stress (PON1 and total antioxidant capacity
(TAC)). In addition, serum albumin and cholesterol were
measured. The decrease in these two analytes in canine
IBD has been associated with a worse histological score,
because they are lost due to damaged intestinal villi and
lacteals [27]. Albumin concentrations are also related to
the severity of IBD in humans [28], and in dogs [10]. In
human IBD patients, cholesterol levels show a negative
correlation with disease activity [29]. CRP concentrations
were measured using an immunoturbidimetric assay (CRP
OSR 6147 Olympus Life and Material Science Europe
GmbH, Hamburg, Germany) [30]. PON1 activity was de-
termined using p-nitrophenyl acetate as substrate [31].
Serum TAC was measured by the method proposed by
Erel et al. [32] with a minimum detection limit of
0.01 mmol/L. Total cholesterol and albumin analyses were
performed using commercially available kits. All assays
were performed in an automated clinical chemistry
analyzer (Olympus AU600, Olympus Diagnostica GmbH,
Freiburg, Germany).
To assess changes in gut microbiota, fecal samples were
analyzed by PCR-restriction fragment length polymorph-
ism (PCR-RFLP). Samples were collected at the initial visit
and 120 days after treatment was initiated. All analyses
were performed by a single investigator (MCC). Immedi-
ately after collection, 1 g of fecal sample was placed in
3 mL of 98 % grade ethanol and cool transported to
CReSA lab (campus Autonomous University of Barcelona
(UAB, Barcelona, Spain)) where it was kept at 4 °C until
DNA extraction, as described elsewhere [33, 34]. A sample
of 400 mg from the ethanol-preserved feces was washed
twice with sterile buffered peptone water. DNA was ex-
tracted using the QIAamp DNA Stool Minikit (Qiagen
Inc., Chatsworth, CA) following the manufacturer’s in-
structions with minor modifications including a lysozyme
incubation step and adding Ribonuclease-A and BSA
(Sigma Chemical Co., St. Louis, MO, USA) to the
eluted DNA [35]. The 16S rDNA was amplified as
previously described [35]. Aliquots of the amplified
DNA fragments were digested in separate tubes with 5
restriction endonucleases (Alu I, Rsa I, Hpa II, Sau
3A I, Cfo I; F. Hoffmann-LaRoche Ltd. Group, Basel,
Switzerland). The endonuclease fragments were resolved
in 2 % agarose gels at 150 V for 60 min. DNA bands were
visualized using an imaging system (UV Chemigenious
Image System; SynGene, Cambridge, UK) and the
GeneSnap software (SynGene, Frederick, MD). Dendro-
grams showing the percentage of similarity among PCR-
RFLP band patterns were generated on the basis of the
Manhattan distance [36].
In order to evaluate histologic changes, upper and lower
gastrointestinal endoscopies were performed at the initial
visit and after 180 days of treatment. Multiple biopsy sam-
ples from stomach (4–8 samples, considered adequate by
the pathologist (ARB)), small intestine (8–18 samples) and
large intestine (8–18 samples) were obtained using differ-
ent flexible video endoscopes depending on the size of the
patient (Fujinon® EG-200FP, EG-270NS and EC-200LR,
Fujifilm Holdings Corporation, Tokyo, Japan) and sent to
Citopath Pathology Service (private laboratory) (UCM) for
microscopic review. Samples were fixed in formalin,
routinely processed, and embedded in paraffin. Serial
sections from paraffin tissue blocks were cut for routine
hematoxylin and eosin staining. Microscopic examination
(Leica DM2000 LED Professional Microscope with
MC170 HD Digital Camera, Leica Biosystems, Barcelona,
Spain) of all tissues was performed by a single pathologist
(ARB) who was blinded to treatments, and objectively
graded endoscopic specimens following the WSAVA
(World Small Animal Veterinary Association) histopatho-
logic Guidelines for the Diagnosis of Idiopathic Inflamma-
tory Bowel Diseases in Dogs and Cats [37]. Histologic
scores for stomach, duodenum and colon were also evalu-
ated and compared between groups.
Concomitant treatments were recorded for all animals
during the study, and relapse rates were compared be-
tween groups.
Statistical analysis
Statistical analysis was performed by a biostatistician
(SMS) with the use of statistical software.2 A one-way
analysis of variance (ANOVA) of repeated measures and
an uncorrected Fisher’s Least Significant Difference
(LSD) test were used to compare the values obtained at
different times during treatment with the pretreatment
values. Unpaired t-test was performed to compare values
between groups at each visit. Fisher’s exact test was per-
formed to analyze differences in relapse rates between
groups. Analytes that did not follow a parametric distri-
bution were log-transformed before applying the test.
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Results
During the study period, 35 dogs were assessed for eligi-
bility (33 recruited by CPV Raspeig, Alicante; 1 by CV
Mediterráneo, Madrid; and 1 by HV Tomás Bustamante,
Cantabria) and 27 of them were randomized into the
clinical trial (Fig. 1). Of the 27 dogs enrolled, 14 were
randomized to Group A (placebo) and 13 to Group B
(supplement). Breeds included Yorkshire terrier (6), cross-
breed (5), poodle (2), French bulldog (2), Samoyed (2),
German shepherd (2), and 1 dog each of the following
breeds: Basset hound, Lhasa Apso, Great Dane, Siberian
Husky, Shar-Pei, Chihuahua, Beagle, and miniature
schnauzer; 19 of the dogs were males and 8 were females,
ranging in age from 1 to 15 years (mean 4.85 ± 3.63 years).
A total of four dogs (14.8 %) did not complete the study.
In Group A, one dog discontinued the intervention due to
owner decision; in Group B, 2 dogs were excluded due to
owner decision (non-compliance) and 1 dog was lost to
follow-up. Overall, 13 dogs in Group A (9 with second en-
doscopy) and 10 dogs in Group B (7 with second endos-
copy) completed the full clinical trial.
Canine IBD activity index
Figure 2 shows changes in median CIBDAI scores. At
the time of diagnosis, there were no significant dif-
ferences (p = 0.62) between groups (median (25th–75th
percentile): placebo = 7 (4.75–8), supplement = 8 (5.5–8)).
After treatment, a significant reduction in median CIBDAI
scores was observed in both groups (p < 0.001). Compared
to baseline median CIBDAI scores, the supplement group
showed a 2-fold decrease (p < 0.01) and a 4-fold decrease
(p < 0.001) after 1 and 60 days of treatment, respectively.
In the placebo group, decreases in median CIBDAI scores
after 30 and 60 days of treatment were 1.75-fold (p < 0.05)
and 3.5-fold (p < 0.01), respectively. No significant differ-
ences between groups were found at any time point.
Fig. 1 Flow diagram of IBD dogs. Group A, placebo; group B, supplement
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Serum biomarkers
Initially, there were no statistically significant differences
(p > 0.05) between groups for any of the serum bio-
markers analyzed. Initial median (25th–75th percentile)
values were within the reference ranges of our
laboratory, with the exception of a decreased PON1 in
all dogs (placebo = 1.7 (1.58–2.21); supplement = 2.02
(1.88–2.57); reference values = 3–4.3 IU/mL), increased
CRP in the placebo group (13.5 (5.0–17.8); reference
values <12 μg/mL), and decreased TAC in the supplement
group (0.25 (0.16–0.36); reference values >0.35 mM/L).
Compared with pretreatment values, the supplement
group showed significantly increased cholesterol and
PON1 after 30 and 60 days of treatment (p < 0.05) and a
significantly decreased TAC was observed in the placebo
group from 90 days of treatment (p < 0.05). When
groups were compared, the supplement group showed
significantly higher cholesterol after 60 (p < 0.05), 90
(p < 0.01) and 120 (p < 0.01) days of treatment, and sig-
nificantly higher (p < 0.01) PON1 after 60, 90, 120 and
180 days of treatment compared to placebo. During the
study, in each group one dog showed cholesterol values
above the reference range (120–300 mg/dL) and one
below it. PON1 remained below the reference range
(3–4.3 IU/mL) in all dogs in the placebo group. The pla-
cebo group showed significantly lower TAC levels after
120 days of treatment (p < 0.05) (Fig. 3). All dogs in the
study showed TAC values below the reference range
(>0.35 mM/L) at some time point, but only with the sup-
plement all dogs finished the study with levels within it.
No significant changes were seen for the other serum
biomarkers.
Histologic examinations
Variations in histologic scores are shown in Fig. 4. At
the time of diagnosis, there were no significant differ-
ences between groups in overall WSAVA histologic
scores (median (25th–75th percentile) group A = 15
(12.5–18); group B = 23 (17–25); p = 0.09). A second bi-
opsy was not possible in 3 of the 19 patients that fin-
ished the study without needing the rescue protocol
(placebo: n = 1; supplement: n = 2) due to reluctance of
some owners to put their pet through another anesthetic
procedure. After treatment, the supplement group
showed a significant 1.53-fold decrease (p < 0.01) in me-
dian overall histologic score, whereas a non-significant
1.07-fold decrease (p = 0.63) was observed in the placebo
group. With the supplement, a significant decrease was
seen in duodenum (p = 0.02) and colon (p = 0.0013). No
statistically significant differences were found with the
placebo for any tissue. When groups were compared,
there were no significant differences at any time point.
Gut microbiota
The dendrogram formed with the band patterns gener-
ated by PCR-RFLP of the fecal samples is shown in Fig. 5.
No bands were generated in the PCR-RFLP electrophor-
esis gel from samples belonging to two animals from
different groups, probably due to an insufficient amount
of DNA. Consequently, these two study subjects were
Fig. 2 One-way ANOVA CIBDAI scores in group A (placebo) and B (supplement) 15 days before treatment start (1), and at 30 (2), 60 (3), 90 (4), 120 (5)
and 180 (6) days of treatment. Asterisks indicate statistical significance compared to pretreatment values (*p < 0.05; **p < 0.01; ***p < 0.001; ****p< 0.0001)
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excluded from the dendrogram. All but two samples were
grouped in two main clusters at similarity levels of 62 and
72 %, respectively. Before and after treatment, samples
from both the placebo and the supplement groups were
not grouped together, but scattered throughout the den-
drogram instead. Thus, no differences were observed
between the placebo and the supplement groups or be-
tween initial and final samples of either group.
Clinical relapses and side effects
During the study, clinical relapses were observed in 3/14
dogs in the placebo group (21.4 %) and in 1/13 dogs in
the supplement group (7.7 %). No statistically significant
differences were found in the proportion of animals that
relapsed in each group (p = 0.59). In the placebo group,
two dogs relapsed at 60 and 90 days of treatment and re-
ceived the rescue protocol. The third dog in the placebo
group relapsed after 30 days of treatment, and received
oral prednisone 1 mg/kg SID for 10 days. In the supple-
ment group, one case relapsed after 90 days of treatment
and started the rescue treatment. Overall, both treat-
ments were well tolerated and no side effects were re-
ported in any of the groups.
Discussion
The etiology of canine IBD is not fully understood, but
there are some factors that are thought to be implicated
in causing intestinal inflammation including an abnor-
mal immune response, genetic susceptibility, nutrition
and the intestinal microbiota [3–5]. Herein, we report
preliminary data on the efficacy and safety of a dietary
supplement containing CS and prebiotics in dogs with
IBD, which might suggest its usefulness to further ex-
tend clinical remission periods and avoid excessive usage
of glucocorticoids and antibiotics, hence minimizing
their unwanted side effects.
A significant decrease in CIBDAI was observed in both
groups at the end of the study. This clinical improve-
ment regardless of the treatments received may be
explained by a positive response to the hydrolyzed diet
alone [4, 9].
To the authors’ knowledge, this is the first study to
report measurements of PON1 in dogs with biopsy-
confirmed IBD. Initially, serum values below our labora-
tory reference range for PON1 were found in all study
dogs, which is in line with what has been observed in
human patients with IBD [16]. After treatment, an in-
creased PON1 was observed only in the supplement
group. This could reflect a protective effect of the sup-
plement against higher oxidative stress occurring in IBD.
In addition, in our study, serum cholesterol increased
only in the supplement group. This could indicate an
improvement in the IBD since a decrease in serum chol-
esterol has been related to a worse histological score in
dogs with IBD, probably because damaged intestinal villi
and lacteals produce cholesterol loss [27]. In human IBD
patients, cholesterol levels show a negative correlation
with disease activity and inflammatory indices [29]. No
significant changes in CRP were observed after treat-
ment in this study. Although increased concentrations of
Fig. 3 Concentrations of serum cholesterol (a), PON1 (b) and TAC
(c) in groups A (placebo) and B (supplement) at the initial visit (1; 15 days
before treatment start), and at 30 (2), 60 (3), 90 (4), 120 (5) and 180 (6)
days of treatment. Asterisks indicate statistical significance compared to
pretreatment values within each group (one-way ANOVA; *p < 0.05;
**p < 0.01). Differences between groups are also represented (unpaired
t-test; ϕp < 0.05; ϕϕp < 0.01)
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Fig. 4 WSAVA histologic scores (overall and for each specific tissue–stomach, colon and duodenum) in groups A (placebo) and B (supplement)
at initial visit (1) and after 180 days of treatment (2; 195 days after initial visit) treatment. Asterisks indicate statistical significance compared to
pretreatment (t = 0 days) values (one-way ANOVA; *p < 0.05; **p < 0.01; ns not statistically significant)
Fig. 5 Ecological changes in microbial populations measured by PCR-RFLP from fecal samples from groups A (placebo) and B (supplement) at
initial visit (1) and at the end of the treatment (2; 135 days after first measurement). The dendrogram illustrates the percentage of similarity
among DNA band patterns
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CRP have been correlated with clinical disease activity in
human patients with IBD and this marker is considered
adequate for evaluating response to treatment in canine
IBD [1, 38], other studies found that CRP was not a
good indicator of disease severity in dogs [39]. We found
significantly decreased TAC values after treatment only
with the placebo, which could indicate a higher suscepti-
bility to oxidative tissue damage compared to the
supplement group. The differences found in our study be-
tween PON1 and TAC might be explained by the fact that
TAC measures all the antioxidants of a sample, since it
represents the measurement of the amount (in moles) of a
free radical scavenged by a test solution [40, 41], and in-
cludes many antioxidants in addition to PON1. Therefore,
depending on the behaviour of the different individual
antioxidants, differences might appear between values of
PON1 (which is just one component) and TAC (which is
the sum of all antioxidants). In addition, PON1 is also
affected by inflammation in dogs [15], which could also
contribute to its different behaviour. Overall, serum re-
sults from this study could suggest a reduction of oxida-
tive stress in the supplement group.
Compared to baseline histologic scores, a significant
improvement was seen only in the supplement group.
Furthermore, these significant improvements were lim-
ited to the small and large intestines (especially the
colon), which corresponds with the target tissues of the
supplement. Nevertheless, the difference between groups
in median WSAVA histologic score after treatment did
not reach the level of statistical significance.
In our study, a clear change in microbial population
was not seen in both groups despite the administration
of prebiotics. This could be attributable to the hetero-
geneity of our study subjects, which belonged to differ-
ent breeds, age groups, and geographical regions with
different environmental conditions. It could also be re-
lated to the small sample size of the study. Moreover,
this concurs with the findings of another recent study
describing clinical improvements in dogs with IBD after
medical therapy which were not accompanied by signifi-
cant changes in their fecal microbiome [5].
Clinical relapses were seen earlier and more frequently
in dogs belonging to the placebo group, although differ-
ences between groups were not statistically significant
probably due to the study being underpowered.
Although the results of the present study provide use-
ful information about the effects of CS and prebiotics in
dogs with IBD, there are some limitations that should be
mentioned. First, the sample size was small and this
might have affected the level of statistical significance of
certain parameters. Due to this concern, although better
serological results were obtained with the supplement
indicating and improved intestinal absorption capacity
and decreased inflammation and oxidative stress, the
observed improvements in histopathology and CIBDAI
could not be statistically supported. It should also be
mentioned that male dogs and Yorkshire terriers were
overrepresented in this study, and that most cases came
from one veterinary center (CPV Raspeig). Lastly, PCR-
RFLP was selected as the technique for evaluating
changes in gut microbiota. Ideally, other methods could
have been used, but the authors chose PCR-RFLP based
on prior publications reporting its usefulness [35, 42].
Conclusions
Our results suggest a beneficial effect of long-term oral
administration of a dietary supplement containing CS and
prebiotics combined with a hydrolyzed diet in dogs with
IBD by increasing serum PON1, TAC and cholesterol in
dogs with IBD. The administration of the supplement over
180 days was safe. A supplemental effect to dietary
treatment was not statistically demonstrated for CIBDAI,
histology and relapse rates, likely because the study was
underpowered. Further studies with larger randomized
clinical trials are warranted to confirm these results.
Endnotes
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